Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting
Rhea-AI Summary
Axsome Therapeutics (NASDAQ: AXSM) is presenting new SYMBRAVO migraine data at the American Headache Society 68th Annual Scientific Meeting in Orlando, June 4–7, 2026. Four posters cover post-hoc efficacy and safety analyses, comparative efficacy versus gepants, and sustained pain relief outcomes from Phase 3 MOMENTUM, MOVEMENT, and INTERCEPT trials.
Positive
- None.
Negative
- None.
News Market Reaction – AXSM
In the Jun 4 session, AXSM declined 0.86%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 01 | Awareness partnership | Neutral | -1.8% | Partnered with Headache Alliance to support migraine awareness initiatives and resources. |
| May 27 | Investor conferences | Neutral | +0.1% | Announced participation in multiple June 2026 investor conferences and webcasts. |
| May 26 | Clinical data presentations | Neutral | -0.8% | Presented new AUVELITY and solriamfetol data at ASCP 2026 in Miami. |
| May 07 | Awareness campaign | Neutral | -1.1% | Recognized Mental Health Month and highlighted mental‑health resources and activities. |
| May 05 | Investor conferences | Neutral | -0.3% | Planned May 2026 health care conference fireside chats with webcast replays. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has focused on awareness campaigns, conferences, and data presentations, with mostly modest single-day price moves and no clear pattern of strong positive reactions.
Over the past month, Axsome’s headlines have centered on conferences, awareness initiatives, and new data. In May–June 2026, the company announced investor conference participation, mental health and migraine awareness campaigns, and AUVELITY data presentations. These items produced modest -1–0%-range price moves. Today’s SYMBRAVO data presentations at AHS fit this pattern of ongoing scientific and promotional activity across the CNS portfolio.
Key Terms
meloxicam medical
rizatriptan medical
migraine medical
post-hoc medical
network meta-analysis medical
phase 3 medical
acute treatment medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL.
Details of the presentations are as follows:
- Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM
Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET
Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY
Poster Number: T19
- Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis
Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET
Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA
Poster Number: T24
- Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials
Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET
Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN
Poster Number: T30
- Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM
Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET
Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY
Poster Number: T33
About Axsome Therapeutics
Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X.
Forward Looking Statements
Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Investors:
Ashley Dong
Senior Director, Investor Relations
(929) 687-1614
adong@axsome.com
Media:
Darren Opland
Senior Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
